To improve the sensitivity of detecting GC, we included 78 GC patients and 124 healthy individuals in the training set (Supplemental Table S2) and divided them into three groups: RNF180 and SFRP2 (RS), a tumor marker group (CEA, CA125, and CA199), and a group with RS + tumor marker. This evidence concerns the gene SFRP2 and gastric cancer.